JPC vs ADPT Comparison

Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its primary investment objective is to provide high current income, and its secondary investment objective is total return. The fund invests a majority of its assets in preferred securities and other income-producing securities, including hybrid securities such as contingent capital securities, and the rest of its investments are made in other securities, mainly income-oriented securities such as corporate and taxable municipal debt and common equity.

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).